Research Opportunity Announcements

To increase awareness of ongoing mental health research, NAMI National creates “Research Opportunity Announcements” to ensure our grassroots leaders are aware of both clinical trials and social sciences research relevant to the mental health community. Promoted research may be conducted by government, academic or private industry partners, or any other entity that has secured IRB approval/exemption for their study. 

Researchers who have secured IRB approval/exemption for their studies may submit an application requesting a partnership with NAMI.

As we take our role in sharing this information very seriously, all studies selected for promotion have been thoroughly reviewed to ensure the safety of those involved. If you have any questions about Research Opportunity Announcements or a study that has been shared by NAMI, please contact us at [email protected].

New This Month

Clinical Research Study: Social Processes

• This is a clinical research study examining the relationship between social interaction and brain activity, mood, and thinking patterns for adults with schizophrenia or another psychotic disorder. The study takes place in Boston, Massachusetts. For more information, please see the NAMI Research Opportunity Announcement.

Clinical Trial: Mobile Application for Depression (BeWell Study)

• This study is a fully remote clinical trial evaluating the impact of a well-being mobile application (app) known as the Healthy Minds Program for people experiencing depression. The study is currently seeking participants across the United States. For more information, please see the NAMI Research Opportunity Announcement.

Survey Study: Ethics of Mental Health Mobile Applications

• This study is a confidential and anonymous online survey to gather adults’ views on the ethics (privacy and safety) of mental health apps. Mental health apps include mood trackers, therapy apps, mindfulness apps, etc. Participants will receive a $20 gift card for completing the survey. For more information, please see the NAMI Research Opportunity Announcement.

 

Current Opportunities

Clinical Trial: Investigational Medication for Schizophrenia (DIAMOND 2 study)

• This study is a clinical research trial for the investigational medication SEP-363856 to determine if the medication is safe and effective for reducing symptoms of acute psychosis in adults with schizophrenia. The study is currently seeking participants across the United States with study sites located in 10 states. Qualified participants may be compensated for their time and travel. For more information and specific study site locations, please see the following NAMI Research Opportunity Announcements: Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, Mississippi, North Carolina, and Texas.

Survey Study: Experiences with REMS Programs for Clozapine

• Risk evaluation and mitigation strategy (REMS) programs are a federally mandated part of taking certain medications and can include various types of patient monitoring, prescribing restrictions, and physician and pharmacy training and certification. This study is designed to better understand individual experiences with REMS programs as a requirement of taking the medication clozapine (Clozaril) via remote, phone-based qualitative interviews. The study is currently seeking participants across the United States. For more information, please see the NAMI Research Opportunity Announcement.

Clinical Trial: Investigational Medication for Schizophrenia

• EMERGENT-5 study
  • This study is a clinical research trial for the investigational product KarXT (combination xanomeline-trospium). The trial will determine if KarXT is safe and effective in treating symptoms of schizophrenia in adults. Participants will receive payment for completed study visits and for completion of digital biomarker assessment surveys. The study is currently seeking participants across the United States. For more information, please see the NAMI Research Opportunity Announcement.  
• ARISE study 
  • This study is a clinical research trial for the investigational medication KarXT (combination xanomeline-trospium) to determine if the medication is safe and effective in treating symptoms of schizophrenia in combination with another antipsychotic medication. Individuals joining the study will receive compensation for their participation. The study is currently seeking participants across the United States. For more information, please see the NAMI Research Opportunity Announcement. 

Clinical Trial: Investigational Medication for PTSD

• This study is a clinical research trial to determine if the investigational drug BI 1358894 is safe and effective for reducing symptoms of PTSD. The study is currently seeking participants across the United States. Reimbursement for study-related travel may be provided. For more information, please see the NAMI Research Opportunity Announcement. 

Clinical Trial: Investigational Medication for MDD

• This study is a clinical research trial to determine if the oral medication BI 1358894 is safe and effective in patients with Major Depressive Disorder (MDD) who have not responded to other forms of treatment. Participants will receive compensation for their time and travel. The study is currently seeking participants in various countries, including the United States. For more information, please see the NAMI Research Opportunity Announcement.   

Clinical Trial: Investigational Medication for Bipolar Depression

• This study is a clinical research trial for a medication to treat depression in people who have been diagnosed with bipolar I disorder. The trial will determine if this investigational medication is safe and effective in patients with major depressive episodes associated with bipolar I disorder who have not responded to other forms of treatment or have experienced adverse side effects with other treatments. Reimbursement may be available for travel and associated costs throughout the duration of the study. The study is currently seeking participants in various countries, including the United States. For more information, please see the NAMI Research Opportunity Announcement.